Literature DB >> 21935637

Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response.

Dietmar Rudolf Thal1, Kelly Del Tredici, Albert C Ludolph, Jeroen J M Hoozemans, Annemieke J Rozemuller, Heiko Braak, Uwe Knippschild.   

Abstract

Granulovacuolar degeneration (GVD) is characterized by the presence of vacuolar cytoplasmic lesions in nerve cells of the medial temporal lobe. These changes occur in older non-diseased individuals as well as in patients with Alzheimer's disease (AD), progressive supranuclear palsy (PSP), Pick's, sporadic Parkinson's (PD), and Guam diseases. We stained representative paraffin sections from all parts of the brain with anti-pTDP43, anti-CK1δ or anti-CK1ε from 14 non-demented elderly, 19 AD, 17 non-AD tauopathy, 9 sporadic PD, and 5 TDP43-proteinopathy [amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD)] cases. Our results showed five stages of GVD based on its distribution pattern: GVD began in the hippocampal subfields CA1, CA2, and the subiculum. In a second stage, entorhinal cortex, and CA4 neurons exhibited GVD. Additional neurons were involved in the temporal neocortex in stage 3, whereas the affection of the amygdala and/or the hypothalamus marked stage 4. A fifth and final stage was characterized by additional GVD in the cingulate cortex and occasionally in the frontal and parietal cortices as well as in the oral raphe and pedunculopontine tegmental nuclei. The GVD stages correlated with neurofibrillary tangle stages, Consortium to Establish a Registry for AD (CERAD) scores for neuritic plaque pathology, amyloid β-protein deposition phases, cerebral amyloid angiopathy stages, and clinical dementia rating (CDR) scores. No associations were seen between GVD stage and the presence of non-AD tauopathies, PD, ALS, or FTLD cases. In conclusion, GVD affects neurons in a hierarchical sequence that allows the distinction of five stages. The topographic distribution of GVD restricted to regions involved in response to chronic stress could indicate a link between GVD and chronically stressful influences. Moreover, the association of the GVD stages with those of AD-related pathology but not with other neurodegenerative disorders points to a possible role of GVD and the response to chronic stress in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21935637     DOI: 10.1007/s00401-011-0871-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  36 in total

1.  Hydroxynonenal-generated crosslinking fluorophore accumulation in Alzheimer disease reveals a dichotomy of protein turnover.

Authors:  Xiongwei Zhu; Rudy J Castellani; Paula I Moreira; Gjumrakch Aliev; Justin C Shenk; Sandra L Siedlak; Peggy L R Harris; Hisashi Fujioka; Lawrence M Sayre; Pamela A Szweda; Luke I Szweda; Mark A Smith; George Perry
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

2.  An Epigenetics-Based, Lifestyle Medicine-Driven Approach to Stress Management for Primary Patient Care: Implications for Medical Education.

Authors:  Jenny Lee; Frank Papa; Paresh Atu Jaini; Sarah Alpini; Tim Kenny
Journal:  Am J Lifestyle Med       Date:  2019-05-09

Review 3.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

4.  Alzheimer's Disease and Protein Kinases.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

Review 6.  Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D).

Authors:  Pengfei Xu; Chiara Ianes; Fabian Gärtner; Congxing Liu; Timo Burster; Vasiliy Bakulev; Najma Rachidi; Uwe Knippschild; Joachim Bischof
Journal:  Gene       Date:  2019-07-31       Impact factor: 3.688

7.  Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons.

Authors:  Leo F McCluskey; Felix Geser; Lauren B Elman; Vivianna M Van Deerlin; John L Robinson; Virginia M-Y Lee; John Q Trojanowski
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-05-09       Impact factor: 4.092

8.  Pathology of clinical and preclinical Alzheimer's disease.

Authors:  Dietmar Rudolf Thal; Christine von Arnim; W Sue T Griffin; Haruyasu Yamaguchi; Robert E Mrak; Johannes Attems; Ajeet Rijal Upadhaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

9.  Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles.

Authors:  Sally Hunter; Thais Minett; Tuomo Polvikoski; Elizabeta Mukaetova-Ladinska; Carol Brayne
Journal:  Alzheimers Res Ther       Date:  2015-08-28       Impact factor: 6.982

Review 10.  The unfolded protein response in neurodegenerative diseases: a neuropathological perspective.

Authors:  Wiep Scheper; Jeroen J M Hoozemans
Journal:  Acta Neuropathol       Date:  2015-07-26       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.